BPC-157 and TB-500 are both peptides studied for tissue repair and are frequently discussed together, sometimes referred to as the "Wolverine Stack" when combined. BPC-157 is a synthetic 15-amino-acid peptide derived from human gastric juice. TB-500 is the synthetic form of thymosin beta-4, a peptide that occurs naturally in the body. Neither is FDA-approved for human use.
At a glance
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | Synthetic 15-amino-acid peptide from human gastric juice, studied for tissue repair and gut healing | Synthetic version of thymosin beta-4, studied for cell migration, angiogenesis, and tissue repair |
| How it's thought to work | Studied for enhancing fibroblast activity, collagen synthesis, angiogenesis, and growth factor activity; also dopamine and serotonin systems | Promotes actin polymerization and cell migration, supports angiogenesis, reduces inflammation, distributes systemically |
| Regulatory status | FDA Category 2 substance; WADA prohibited; not FDA-approved for any human use | WADA prohibited substance; not FDA-approved for any human use |
| Strength of evidence | Extensive preclinical (animal and lab) data; human clinical trials remain limited | Preclinical (animal and lab) studies; human data is limited |
| Reported side effects | Minimal: occasional injection site redness or irritation, rare mild dizziness or nausea | Rare: fatigue, temporary mood changes, injection site reactions |
| Common vial sizes | 5mg, 10mg | 5mg, 10mg |
| Mixing math example | 5 mg + 1 mL BAC water = 5,000 mcg/mL, 50 mcg per unit | 5 mg + 1 mL BAC water = 5,000 mcg/mL, 50 mcg per unit |
Key differences
BPC-157 is studied for enhancing fibroblast activity, collagen synthesis, and angiogenesis, along with effects on dopamine and serotonin systems. TB-500 is studied for promoting actin polymerization and cell migration, supporting angiogenesis, and reducing inflammation, with systemic distribution described as supporting whole-body recovery rather than effects limited to one site.
BPC-157 is classified as an FDA Category 2 substance and is prohibited by WADA; it is not FDA-approved for any human use. TB-500 is also a WADA-prohibited substance and is likewise not FDA-approved.
BPC-157's reported side effects are minimal: occasional injection site redness or irritation and rare mild dizziness or nausea. TB-500's reported side effects are also described as rare: fatigue, temporary mood changes, and injection site reactions. Long-term human safety data is limited for both.
What the research covers
BPC-157 has an extensive preclinical (animal and lab) evidence base showing accelerated tissue repair, while human clinical trials remain limited. TB-500's evidence base is also preclinical, with animal and lab studies showing tissue repair and anti-inflammatory effects; human data on TB-500 is likewise limited. Neither compound's evidence base currently includes large human clinical trials.
Frequently asked questions
What is the difference between BPC-157 and TB-500?
BPC-157 is derived from a compound in human gastric juice and is studied for fibroblast activity and collagen synthesis. TB-500 is the synthetic form of thymosin beta-4 and is studied for actin polymerization and systemic cell migration.
Is BPC-157 or TB-500 FDA-approved?
Neither is FDA-approved for human use. BPC-157 is an FDA Category 2 substance; both are WADA-prohibited substances.
Which has more human research, BPC-157 or TB-500?
Both rely mainly on preclinical, animal and lab data. Human clinical trial data is limited for both compounds.
Are BPC-157 and TB-500 the same thing?
No. They are separate peptides with different origins and studied mechanisms, though they are often discussed together because of their overlapping tissue-repair research.
Both entries, plus the calculator
The PeptidesAI app covers BPC-157, TB-500 and 68 other compounds, with a reconstitution calculator, a dose log and reminders. Free to download on iPhone.
Download on the App Store